Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver

NCT00803647 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT00803647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00803647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
November 30, 2014
Enrollment
20 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer